270 related articles for article (PubMed ID: 17472721)
1. B-lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout mice.
Hayakawa I; Tedder TF; Zhuang Y
Immunology; 2007 Sep; 122(1):73-9. PubMed ID: 17472721
[TBL] [Abstract][Full Text] [Related]
2. Analysis of IgM antibody production and repertoire in a mouse model of Sjögren's syndrome.
Kramer JM; Holodick NE; Vizconde TC; Raman I; Yan M; Li QZ; Gaile DP; Rothstein TL
J Leukoc Biol; 2016 Feb; 99(2):321-31. PubMed ID: 26382297
[TBL] [Abstract][Full Text] [Related]
3. Primary Sjögren's syndrome and deficiency of ICA69.
Winer S; Astsaturov I; Cheung R; Tsui H; Song A; Gaedigk R; Winer D; Sampson A; McKerlie C; Bookman A; Dosch HM
Lancet; 2002 Oct; 360(9339):1063-9. PubMed ID: 12383988
[TBL] [Abstract][Full Text] [Related]
4. Modeling Sjögren's syndrome with Id3 conditional knockout mice.
Guo Z; Li H; Han M; Xu T; Wu X; Zhuang Y
Immunol Lett; 2011 Mar; 135(1-2):34-42. PubMed ID: 20932862
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21-mediated suppression of the Pax3-Id3 pathway exacerbates the development of Sjögren's syndrome via follicular helper T cells.
Park JS; Kim SM; Choi J; Jung KA; Hwang SH; Yang S; Kwok SK; Cho ML; Park SH
Cytokine; 2020 Jan; 125():154834. PubMed ID: 31491724
[TBL] [Abstract][Full Text] [Related]
6. Lacrimal and salivary gland inflammation in the C3H/Ipr autoimmune strain mouse: a potential mode for Sjögren's syndrome.
Johnson BC; Morton JI; Trune DR
Otolaryngol Head Neck Surg; 1992 Apr; 106(4):394-9. PubMed ID: 1565490
[TBL] [Abstract][Full Text] [Related]
7. A T cell intrinsic role of Id3 in a mouse model for primary Sjogren's syndrome.
Li H; Dai M; Zhuang Y
Immunity; 2004 Oct; 21(4):551-60. PubMed ID: 15485632
[TBL] [Abstract][Full Text] [Related]
8. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.
Groom J; Kalled SL; Cutler AH; Olson C; Woodcock SA; Schneider P; Tschopp J; Cachero TG; Batten M; Wheway J; Mauri D; Cavill D; Gordon TP; Mackay CR; Mackay F
J Clin Invest; 2002 Jan; 109(1):59-68. PubMed ID: 11781351
[TBL] [Abstract][Full Text] [Related]
9. Contribution of IL-13 to early exocrinopathy in Id3-/- mice.
Mahlios J; Zhuang Y
Mol Immunol; 2011 Oct; 49(1-2):227-33. PubMed ID: 21924496
[TBL] [Abstract][Full Text] [Related]
10. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
[TBL] [Abstract][Full Text] [Related]
11. Submandibular and lacrimal gland immunoglobulin in the C3H.MRL-Faslpr autoimmune mouse model of Sjögren's syndrome.
Trune DR; Leedy DA
Laryngoscope; 1998 Nov; 108(11 Pt 1):1729-32. PubMed ID: 9818834
[TBL] [Abstract][Full Text] [Related]
12. Sjögren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease.
Gao J; Killedar S; Cornelius JG; Nguyen C; Cha S; Peck AB
J Autoimmun; 2006 Mar; 26(2):90-103. PubMed ID: 16413168
[TBL] [Abstract][Full Text] [Related]
13. Different stages of primary Sjogren's syndrome involving lymphotoxin and type 1 IFN.
Shen L; Suresh L; Malyavantham K; Kowal P; Xuan J; Lindemann MJ; Ambrus JL
J Immunol; 2013 Jul; 191(2):608-13. PubMed ID: 23772034
[TBL] [Abstract][Full Text] [Related]
14. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
15. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
16. A new animal model for primary Sjögren's syndrome in NFS/sld mutant mice.
Haneji N; Hamano H; Yanagi K; Hayashi Y
J Immunol; 1994 Sep; 153(6):2769-77. PubMed ID: 8077681
[TBL] [Abstract][Full Text] [Related]
17. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
18. Is Inhibitor of differentiation 3 involved in human primary Sjögren's syndrome?
Sellam J; Miceli-Richard C; Gottenberg JE; Proust A; Ittah M; Lavie F; Loiseau P; Mariette X
Rheumatology (Oxford); 2008 Apr; 47(4):437-41. PubMed ID: 18296721
[TBL] [Abstract][Full Text] [Related]
19. Development of Sjogren's syndrome in nonobese diabetic-derived autoimmune-prone C57BL/6.NOD-Aec1Aec2 mice is dependent on complement component-3.
Nguyen CQ; Kim H; Cornelius JG; Peck AB
J Immunol; 2007 Aug; 179(4):2318-29. PubMed ID: 17675493
[TBL] [Abstract][Full Text] [Related]
20. Id3 knockout mice as a new model for sjogren's syndrome: only a T cell defect or more?
Versnel MA
Immunity; 2004 Oct; 21(4):457-8. PubMed ID: 15485622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
